By 2022, the global high potency pharmaceutical ingredients market is predicted to reach 25.86
billion dollars. There is an increasing number of aspiring manufacturers that aims to make quick
assistance therapeutics in the budding economies of China and India. This is believed to improve
require over the estimated stage.
There are favourable healthcare reforms and regulations for commercialization and R&D of the novel
high potency active ingredients are expected to enhance the growth of the market during the
predicted period. There has been an increase in number of CMO providing outsourcing services due
to extensive capitalization that is needed for the manufacturing plant setup.
Further findings states that
Synthetic high potency ingredients was the largest in terms of revenue in the year 2014
The overall drug type market was dominated by high potency active ingredients in the year
In the midst of revenue esteemed at over 4.5 billion dollars in 2014, North America was the
main local market.
Within the forecast period, Asia Pacific is expected to register growth with market growing at
a CAGR of 14 percent.
There are several key players of the high potency pharmaceutical ingredients market. Some of these
key players are Pfizer Inc, Covidien Plc, and Sigma Aldrich among many others. They are determined
to enter into some untapped territories through agreements with the local manufactures and different
distributors. This is a viable, effective and sustainable strategy adopted by the key players.
In the year 2014, the cancer treatment section accounted the major share in income because of the
growing command for anti-cancerous medicines. The growing geriatric population base prone to
chronic diseases and levels of awareness concerning the benefits with associated high potency active
ingredients are also some of the key factors contributing to segment the growth.